全文获取类型
收费全文 | 465505篇 |
免费 | 42718篇 |
国内免费 | 14607篇 |
专业分类
耳鼻咽喉 | 4764篇 |
儿科学 | 9782篇 |
妇产科学 | 7182篇 |
基础医学 | 62868篇 |
口腔科学 | 12139篇 |
临床医学 | 37227篇 |
内科学 | 64637篇 |
皮肤病学 | 6508篇 |
神经病学 | 32015篇 |
特种医学 | 10559篇 |
外国民族医学 | 79篇 |
外科学 | 38869篇 |
综合类 | 69800篇 |
现状与发展 | 57篇 |
一般理论 | 25篇 |
预防医学 | 39741篇 |
眼科学 | 5035篇 |
药学 | 53303篇 |
360篇 | |
中国医学 | 34378篇 |
肿瘤学 | 33502篇 |
出版年
2023年 | 7345篇 |
2022年 | 10859篇 |
2021年 | 19276篇 |
2020年 | 18593篇 |
2019年 | 20432篇 |
2018年 | 19044篇 |
2017年 | 17780篇 |
2016年 | 16945篇 |
2015年 | 18255篇 |
2014年 | 30238篇 |
2013年 | 32489篇 |
2012年 | 29293篇 |
2011年 | 32888篇 |
2010年 | 27145篇 |
2009年 | 25000篇 |
2008年 | 23889篇 |
2007年 | 22767篇 |
2006年 | 20079篇 |
2005年 | 17394篇 |
2004年 | 14709篇 |
2003年 | 12678篇 |
2002年 | 9790篇 |
2001年 | 8311篇 |
2000年 | 7126篇 |
1999年 | 5974篇 |
1998年 | 4797篇 |
1997年 | 4304篇 |
1996年 | 3517篇 |
1995年 | 3493篇 |
1994年 | 3156篇 |
1993年 | 2686篇 |
1992年 | 2342篇 |
1991年 | 2124篇 |
1990年 | 1798篇 |
1989年 | 1588篇 |
1988年 | 1435篇 |
1987年 | 1254篇 |
1986年 | 1203篇 |
1985年 | 2870篇 |
1984年 | 3103篇 |
1983年 | 2024篇 |
1982年 | 2510篇 |
1981年 | 1828篇 |
1980年 | 1582篇 |
1979年 | 1381篇 |
1978年 | 1100篇 |
1977年 | 856篇 |
1976年 | 948篇 |
1975年 | 662篇 |
1974年 | 551篇 |
排序方式: 共有10000条查询结果,搜索用时 171 毫秒
991.
目的:研究柴胡皂苷D(saikosaponin-D,SSD)对人结直肠癌细胞SW480迁移和侵袭能力的影响,并初步探讨SSD抑制细胞迁移和侵袭的机制。方法:MTT检测SSD对细胞增殖的影响。划痕实验和Transwell迁移实验研究SSD对细胞迁移能力的影响。Transwell侵袭实验研究SSD对细胞侵袭能力的影响。Western-blot检测SSD对上皮间质转化(epithelial mesenchymal transformation,EMT)相关蛋白(E-cadherin、N-cadherin和Vimentin)表达的影响。克隆球形成实验研究SSD对细胞干性的影响。结果:在划痕实验和Transwell迁移实验中,SSD显著抑制SW480的迁移能力(P<0.05)。在Transwell侵袭实验中,SSD显著抑制SW480的侵袭能力(P<0.05)。SSD处理后,细胞E-cadherin的表达增高,N-cadherin和Vimentin的表达降低(P<0.05),同时SSD抑制SW480细胞克隆球的形成(P<0.05)。结论:柴胡皂苷D通过抑制EMT和细胞干性抑制人结直肠癌细胞SW480的迁移和侵袭。 相似文献
992.
Rohini KhuranaSatyajeet RathHarikesh Bahadur SinghMadhup RastogiSambit Swarup NandaAbhishek ChauhanMohammad KaifNuzhat Hussain 《Asian Pacific journal of cancer prevention》2020,21(3):755-760
Background: The standard of care in high grade glioma (HGG) is maximal safe surgical resection followed by adjuvant radiotherapy (RT) with/without chemotherapy. For anaplastic gliomas, studies have shown use of procarbazine, lomustine, vincristine (PCV) improves overall survival (OS) and progression free survival (PFS). Currently, there is substantial evidence that molecular markers strongly predict prognosis and response to treatment. Methods: Between January 2016 to January 2018, 42 patients were accrued and followed up till April 2019. The primary end points were to correlate molecular markers with response to therapy in terms of OS and PFS in HGG. The secondary end point was to evaluate frequency of 1p/19q codeletion, IDH 1 mutation, ATRX deletion and p53 in HGG patients. Results: The median age was 46 years (range 18-67) with M:F ratio 30:12. The frequency of IDH1 mutation,1p/19q codeletion, p53 mutation and ATRX mutation were 42.8%, 16.6%, 42.8% and 14.2% respectively. All the seven patients with 1p/19q codeletion had IDH1 mutation. Median follow up was 22 months. The 20-months PFS for different mutations were as follows; IDH1-mutated vs wild type: 53.6% vs 29.8%; p-0.035, 1p/19q codeleted vs non-codeleted: 85.7% vs 62.3%; p-0.011, p53 wild type vs mutated 32.1% vs 35.6%; p-0.035 and ATRX lost vs retained: 55.6% vs 53.3%; p- 0.369. The 20-months OS for IDH1 mutated vs wild type: 82.4% vs 30.6%; p-0.014, 1p/19q codeleted vs non-codeleted: 85.7% vs 65.8%; p-0.104, p53 wild-type vs mutated 45.5% vs 73.9%; p-0.036 and ATRX lost vs retained: 100% vs 60.3%; p-0.087. Conclusion: Codeletion of 1p/19q with IDH1 mutation in HGG is associated with a significantly favourable PFS. However, larger studies with longer follow up are required to evaluate OS and PFS in all the molecular subgroups. 相似文献
993.
《Clinical lung cancer》2020,21(5):e405-e414
BackgroundProgrammed cell death 1 (PD-1) inhibitors have become a standard treatment, albeit not completely effective, for patients with advanced non–small-cell lung cancer (NSCLC). Previous studies of advanced melanoma have revealed that the tumor burden predicted the response to PD-1 inhibitors, although this relationship has remained unclear for NSCLC.Patients and MethodsThe present single-center retrospective study evaluated 163 patients with advanced NSCLC who had received PD-1/programmed cell death ligand 1 (PD-L1) inhibitor monotherapy from December 2015 to December 2018. The clinical tumor burden was estimated using the baseline sum of the target lesions’ longest diameters (BSLDs), measured according to the Response Evaluation Criteria for Solid Tumors, and the baseline number of metastatic lesions (BNMLs).ResultsThe optimal cutoff values for predicting progression-free survival (PFS) were 5 for the BNMLs and 76 mm for the BSLDs, using the minimum P value method. The low-BNML group included 73 patients (44.8%). The median PFS was 12.2 months in the low-BNML group and 2.8 months in the high-BNML group (hazard ratio, 0.51; P = .0005). The low-BSLD group included 92 patients (56.4%). The median PFS was 9.6 months in the low-BSLD group and 3.4 months in the high-BSLD group (hazard ratio, 0.52; P = .0006). Multivariable analysis revealed that low-BSLD, low-BNML, nonsquamous histologic type and a PD-L1 tumor proportion score of ≥ 50% were independently associated with prolonged PFS.ConclusionsPD-L1 expression and the clinical tumor burden can predict the efficacy of PD-1/PD-L1 inhibitor monotherapy for NSCLC. 相似文献
994.
995.
996.
997.
《Journal of vascular and interventional radiology : JVIR》2020,31(1):141-149
PurposeTo determine the clinical impact and predictors of slow flow after endovascular treatment (EVT) using the Crosser catheter for debulking infrapopliteal lesions associated with critical limb ischemia.Materials and MethodsThis retrospective study included 65 patients with critical limb ischemia (70 limbs, 90 infrapopliteal lesions), who underwent EVT using the Crosser catheter between November 2011 and February 2017. The Crosser catheter was used when the balloon catheter could not be passed through the lesion or could not be dilated sufficiently. Slow flow was evaluated after atherectomy using Crosser and was defined as delayed antegrade flow to the foot (total number of cine frames >35).ResultsFollowing atherectomy, slow flow developed in 37 infrapopliteal lesions (41.1%). Despite secondary treatment, slow flow persisted in 29 of 37 lesions (78%). After atherectomy using the Crosser catheter, the balloon could be passed through the lesion in all cases. The wound healing rate at 1 year after EVT (overall, 67.8%) was significantly poorer in the presence of slow flow (rate with vs. without slow flow, 45.3% vs. 84.4%, respectively; P = .006), especially among patients with stage ≥3 baseline wound, ischemia, and foot infection. The active length of the Crosser catheter was a predictor of slow flow (odds ratio, 1.05; 95% confidence interval, 1.03–1.08; P < .001), with an optimal cutoff of 100 mm.ConclusionsSlow flow is associated with a poorer wound healing rate at 1 year, especially for patients with severe baseline ischemia. To reduce the risk of slow flow, the active length of the Crosser catheter should be kept at <100 mm. 相似文献
998.
Jin Ge Emily R. Perito John Bucuvalas Richard Gilroy Evelyn K. Hsu John P. Roberts Jennifer C. Lai 《American journal of transplantation》2020,20(4):1116-1124
Split liver transplantation (SLT) is 1 strategy for maximizing the number of deceased donor liver transplants. Recent reports suggest that utilization of SLT in the United States remains low. We examined deceased donor offers that were ultimately split between 2010 and 2014. SLTs were categorized as “primary” and “secondary” transplants. We analyzed allocation patterns and used logistic regression to evaluate factors associated with secondary split discard. Four hundred eighteen livers were split: 54% from adult, 46% from pediatric donors. Of the 227 adult donor livers split, 61% met United Network for Organ Sharing “optimal” split criteria. A total of 770 recipients (418 primary and 352 secondary) were transplanted, indicating 16% discard. Ninety‐two percent of the 418 primary recipients were children, and 47% were accepted on the first offer. Eighty‐seven percent of the 352 secondary recipients were adults, and 7% were accepted on the first offer. Of the 352 pairs, 99% were transplanted in the same region, 36% at the same center. In logistic regression, shorter donor height was associated with secondary discard (odds ratio 0.97 per cm, 95% CI 0.94‐1.00, P = .02). SLT volume by center was not predictive of secondary discard. Current policy proposals that incentivize SLT in the United States could increase the number of transplants to children and adults. 相似文献
999.
随着社会经济的快速发展,国内医疗事业的竞争日益激烈,医疗机构需要积极提高自身的业务水平和管理水平,才能强化医疗技术水平,获得更多的社会经济效益。在国内医疗体制深化变革的趋势下,纪检监察在医院建设中发挥着越来越重要的作用,主要职责是管理和监督医院各项制度的落实、健康环境的建设等,旨在规范机构医疗服务,提高机构服务质量,促使医院树立良好的社会形象,保障医院的社会经济效益。该文针对医院纪检监察在医院建设中的作用和实施展开分析。 相似文献
1000.
Kristen R. McSweeney Laura K. Gadanec Tawar Qaradakhi Thushira Malindra Gammune Peter Kubatka Martin Caprnda Julia Fedotova Jozef Radonak Peter Kruzliak Anthony Zulli 《Clinical and experimental pharmacology & physiology》2020,47(11):1816-1823
Cardiovascular complications are a side effect of cancer therapy, potentially through reduced blood vessel function. ONC201 (TIC10) is currently used in phase 2 clinical trials to treat high-grade gliomas. TIC10 is a phosphatidylinositol 3-kinase (PI3K)/AKT/extracellular signal-regulated kinase (ERK) inhibitor that induces apoptosis via upregulation of TNF-related apoptosis-inducing ligand, which via stimulation of FOXO and death receptor could increase eNOS upregulation. This has the potential to improve vascular function through increased NO bioavailability. Our aim was to investigate the role of TIC10 on vascular function to determine if it would affect the risk of CVD. Excised abdominal aorta from White New Zealand male rabbits were cut into rings. Vessels were incubated with TIC10 and AS1842856 (FOXO1 inhibitor) followed by cumulative doses of acetylcholine (Ach) to assess vessel function. Vessels were then processed for immunohistochemistry. Incubation of blood vessels with TIC10 resulted in enhanced vasodilatory capacity. Combination treatment with the FOXO1 inhibitor and TIC10 resulted in reduced vascular function compared to control. Immunohistochemical analysis indicated a 3-fold increase in death receptor 5 (DR5) expression in the TIC10-treated blood vessels but the addition of the FOXO1 inhibitor downregulated DR5 expression. The expression of DR4 receptor was not significantly increased in the presence of TIC10; however, addition of the FOXO1 inhibitor downregulated expression. TIC10 has the capacity to improve the function of healthy vessels when stimulated with the vasodilator Ach. This highlights its therapeutic potential not only in cancer treatment without cardiovascular side effects, but also as a possible drug to treat established CVD. 相似文献